Lenz Therapeutics (LENZ) Shares and Market Overview
Lenz Therapeutics (NASDAQ: LENZ) closed the trading session at 09:07 AM Central Europe on Wednesday, 21 May 2026, up 0.92 %. The stock is currently priced at USD 3.19 on major exchanges.
Trading and Liquidity
- Shares outstanding: 31.4 million
- Market capitalization: USD 102 million
- 24‑hour trading volume: USD 2.1 million (approximately 660,000 shares)
- Price change since last month‑end: –19.12 %
Technical Indicators
- 200‑day simple moving average: USD 8.61
- 52‑week high: USD 34.27 (22 October 2025)
- 52‑week low: USD 3.21 (19 October 2026)
Comparative Performance of Related Stocks
| Ticker | 24‑hour change | Current price (USD) | Market cap (USD mn) |
|---|---|---|---|
| AVXL (Anavex Life Sciences) | –4.58 % | 1.36 | 121.4 |
| AREC (American) | –0.88 % | 1.10 | 122.0 |
| ACNT (Ascent Industries) | +0.30 % | 13.78 | 121.5 |
| FEAM (5e Advanced Materials) | –12.29 % | 2.57 | 122.0 |
| BOTJ (Bank of the James) | –0.45 % | 27.47 | 121.9 |
Bank of the James (BOTJ) Highlights
- Price‑to‑earnings ratio: 10.54
- Latest quarterly results:
- Stable operating performance with earnings driven by corporate and ASEAN loan growth.
- Net interest income remained robust, supported by disciplined cost management and efficient funding.
- Credit quality improved, with a modest decline in expected credit losses and a strengthening loan‑loss coverage ratio.
- Capital adequacy remained well above regulatory requirements.
The results suggest a solid foundation for future growth while maintaining prudent risk management practices.
Company Profile – Lenz Therapeutics
Lenz Therapeutics is a biotechnology firm focused on developing potentially curative therapies for patients with serious diseases. The company is headquartered in South San Francisco, United States, and operates globally. Its portfolio includes several pipeline candidates aimed at addressing unmet medical needs across multiple therapeutic areas.